1. In Vivo
  2. >>Global Vision

U3 Pharma AG

 
• By Melanie Senior

German start-up U3 Pharma AG is hoping that its focus on, and understanding of, full biological systems rather than simply on chemistry will give it a chance to win the race to find new cancer drugs.

The illusion that the uncovering of the genome and automated, high-throughput discovery technologies would generate a plethora of new, validated drug leads has long been shattered. Drug discovery companies have had to get cleverer than that. Many focus on well-known target classes, such as G-protein coupled receptors (GPCRs), protein kinases, or the gene families associated with these. Others have tried to carve a niche by going for targets that have for one reason or another proven intractable. (See "Accelerating Small Molecule Drug Discovery," START UP, September 2000 Also see "Accelerating Small Molecule Drug Discovery" - Scrip, 1 September, 2000..)

All are going for speed, though. German start-up U3 Pharma AG is no exception: its goal is to get...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Global Vision

By The Numbers: Phase III Trials In China Skyrocket While Phase I Falls To Earth

 
• By Mainbayar Badarch

China has rapidly expanded its clinical trial footprint since 2015, driven by regulatory reforms and increased investment in pharma R&D. By 2023, it matched the US in trial volume. Oncology leads, but biologics are leading in momentum.

Navigating the GLP-1 Opportunity In China: Strategic Imperatives For Western Pharma

 
• By Jo Shorthouse

The Chinese appetite for GLP-1s is noticeable. While the market opportunity for western pharma is huge, so are the strategic market access challenges, though not unsurmountable, L.E.K. Consulting told In Vivo.

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By Barnaby Pickering

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By Jung Won Shin

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

More from In Vivo

Podcast: Tevard CEO Sees Hope For His Daughter In Company’s tRNA Platform

 
• By David Wild

Tevard Biosciences CEO Daniel Fischer discusses how engineered suppressor tRNAs overcome nonsense mutations, restoring full-length protein production to treat rare genetic diseases like Dravet syndrome.

Execs On The Move: July 2025

 
• By In Vivo Team

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Deals In Depth: July 2025

 
• By Deanna Kamienski and Maureen Riordan

Six $1bn+ alliances were penned in July, and two exceeded $2bn.